In the 1st quarter of 2021, Deerfield invested in DNAMx through its Series A financing. DNAMx is a diagnostic company developing a liquid biopsy cancer diagnostic test through a cell-free Methylated DNA Immunoprecipitation and high-throughput sequencing platform. This enables a non-invasive, early, accurate and cost-effective screening of circulating tumor-derived DNA. The financing will be used to complete the product development plan.